Cohort Study: SGLT2 Inhibitors Associated with Reduced Risk of Heart Failure

Use of sodium glucose cotransporter 2 inhibitors and risk of major cardiovascular events and heart failure: Scandinavian register based cohort study – The BMJ (free)

Commentaries: SGLT2 inhibitors cut heart failure risk for T2D patients – Cardiovascular Business (free) AND Newer diabetes drug drops heart failure risk by 34 percent, study says – UPI (free)

Related observational studies: SGLT2 agents may reduce cardiovascular risk in diabetics (link to abstract and commentaries)